Skip to main content

Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.

Publication ,  Conference
Hong, DS; Schoffski, P; Calvo, A; Sarantopoulos, J; Ochoa De Olza, M; Carvajal, RD; Prawira, A; Kyi, C; Esaki, T; Akerley, WL; De Braud, FG ...
Published in: Journal of Clinical Oncology
May 20, 2018

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

3012 / 3012

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hong, D. S., Schoffski, P., Calvo, A., Sarantopoulos, J., Ochoa De Olza, M., Carvajal, R. D., … Tan, D.-W. (2018). Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. In Journal of Clinical Oncology (Vol. 36, pp. 3012–3012). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.3012
Hong, David S., Patrick Schoffski, Aitana Calvo, John Sarantopoulos, María Ochoa De Olza, Richard D. Carvajal, Amy Prawira, et al. “Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.” In Journal of Clinical Oncology, 36:3012–3012. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3012.
Hong DS, Schoffski P, Calvo A, Sarantopoulos J, Ochoa De Olza M, Carvajal RD, et al. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 3012–3012.
Hong, David S., et al. “Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 3012–3012. Crossref, doi:10.1200/jco.2018.36.15_suppl.3012.
Hong DS, Schoffski P, Calvo A, Sarantopoulos J, Ochoa De Olza M, Carvajal RD, Prawira A, Kyi C, Esaki T, Akerley WL, De Braud FG, Hui R, Zhang T, Soo RA, Maur M, Weickhardt AJ, Roy Chowdhury N, Sabatos-Peyton C, Kwak EL, Tan DS-W. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 3012–3012.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

3012 / 3012

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences